Related Experiment Videos
Antipyretic therapy
1The William Harvey Research Institute, St Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK. r.m.botting@qmul.ac.uk
Frontiers in Bioscience : a Journal and Virtual Library
|February 10, 2004
Summary
Fever reduction can be achieved through physical cooling or medications like acetaminophen. While effective, acetaminophen and NSAIDs have risks, suggesting future antipyretic drugs may target COX-2 inhibitors.
Area of Science:
- Pharmacology
- Internal Medicine
- Drug Development
Background:
- Antipyresis, or fever reduction, is historically achieved via physical methods or pharmacological agents.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) and early analgesics like acetanilide and phenacetin were used for fever since the late 19th century.
- Acetaminophen, a metabolite of earlier drugs, emerged as a preferred antipyretic by the 1950s due to its efficacy.
Purpose of the Study:
- To review the historical use and evolving landscape of antipyretic medications.
- To highlight the toxicities associated with traditional antipyretics, including NSAIDs and acetaminophen.
- To explore the potential of selective COX-2 inhibitors as future antipyretic therapies.
Main Methods:
- Literature review of antipyretic drug development and therapeutic use.
- Analysis of the pharmacological profiles and adverse effects of key antipyretic agents.
- Discussion of the mechanisms and potential benefits of selective COX-2 inhibitors.
Main Results:
- NSAIDs carry risks of gastrotoxicity, such as stomach irritation, ulcers, and bleeding.
- Acetaminophen, despite its popularity, poses a risk of liver toxicity even at slightly supra-therapeutic doses.
- Selective COX-2 inhibitors present a potential alternative, offering reduced gastrointestinal and hepatic side effects.
Conclusions:
- Current widely used antipyretics like NSAIDs and acetaminophen have significant toxicity concerns.
- Selective COX-2 inhibitors demonstrate promise as safer alternatives for fever management.
- Further research and clinical application of COX-2 inhibitors may lead to improved antipyretic strategies.